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Colorectal cancer is the third most common
human cancer and the second most important
cause of cancer-related death in Western
countries, affecting men and women about
equally. The etiology of sporadic colorectal
cancer is relatively poorly understood,
although diet is thought to play an important
role in modifying risk. Vegetables, fruit, and
dietary fiber are protective, whereas red and
processed meats, fat, total energy intake, and
obesity all increase risk (Potter 1996).
Diet is also an important source of expo-
sure to many synthetic organic chemicals
used in industry, agriculture, or accidentally
released to the environment. Among them,
the industrial organochlorine compounds
(OCs) hexachlorobenzene (HCB) and poly-
chlorinated biphenyls (PCBs) and the pesti-
cides DDT (dichlorodiphenyltrichloroethane)
and lindane [γ-hexachlorocyclohexane (HCH),
including α-HCH and β-HCH isomers]
have been classified as “probably” or “possi-
bly” carcinogenic to humans [International
Agency for Research on Cancer (IARC)
1987, 1991]. Most of the data for these
classifications come from animal studies,
although evidence for carcinogenic effects in
humans is accumulating from occupational
and nonoccupational exposure studies
[Agency for Toxic Substances and Disease
Registry (ATSDR) 2000, 2002].
Despite reductions in their use and fugi-
tive release, OCs remain one of the most
important groups of persistent pollutants to
which humans are exposed, primarily via
dietary intake. More lipophilic OCs, and
those that are not easily metabolized, accumu-
late in adipose tissue, and the half-lives of
these compounds in the body can be on the
order of years or decades, whereas those com-
pounds that are more water soluble or more
easily metabolized have half-lives on the order
of hours or days. Eventually, OCs recirculate
in blood and are excreted in feces (Moser and
McLachlan 2001). Serum concentrations are
strongly correlated with fecal concentrations,
particularly for the more lipophilic com-
pounds that accumulate in adipose tissue and
are generally more chlorinated (Juan et al.
2002; Moser and McLachlan 2001). Exposure
of tissue in the gastrointestinal tract to OCs is
the result, therefore, not only of uptake from
food but also of depuration from the tissue to
the lumen. The long residence time
(1–2 days) of feces in the colon offers poten-
tially greater opportunity for exchange of
OCs between the lumen and the epithelium
than elsewhere in the gastrointestinal tract.
However, the physicochemical characteristics
of the compound (speciﬁcally, its solubility in
water) will be more important in determining
the relative importance of these exchange
processes in the colon than in the small intes-
tine, given the predominantly aqueous nature
of the colonic milieu (Moser and McLachlan
2001; Schlummer et al. 1998). Therefore,
colon epithelium is likely to be a major target
for putative carcinogenic effects of OCs via
luminal and blood-borne exposure.
OCs have been shown to mimic hor-
mones, and this has been postulated as a
mechanism for carcinogenesis in hormone-
dependent cancers (Davis et al. 1993).
Although colorectal cancer cannot be consid-
ered a hormone-dependent cancer, there is evi-
dence that hormones play a role, at least in
women: hormone replacement therapy and,
possibly, high parity and oral contraceptive use
are all protective factors (Potter 1999). Studies
of cancers of the pancreas and breast have
shown that OCs may interact with genetic
alterations in tumors such as K-ras mutations
or p53 overexpression (Hoyer et al. 2002;
Porta et al. 1999; Slebos et al. 2000). Research
on these interactions is relevant because they
are frequent in colorectal cancer, and one
potential mechanism of OC toxicity may be
the induction of mutations in these genes.
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Organochlorine compounds have been linked to increased risk of several cancers. Despite reduc-
tions in their use and fugitive release, they remain one of the most important groups of persistent
pollutants to which humans are exposed, primarily through dietary intake. We designed a
case–control study to assess the risk of colorectal cancer with exposure to these chemicals, and
their potential interactions with genetic alterations in the tumors. A subsample of cases (n = 132)
and hospital controls (n = 76) was selected from a larger case–control study in Barcelona,
Catalonia, Spain. We measured concentrations in serum of several organochlorines by gas chro-
matography. We assessed point mutations in K-ras and p53 genes in tissue samples by polymerase
chain reaction/single-strand conformation polymorphism and assessed expression of p53 protein
by immunohistochemical methods. An elevated risk of colorectal cancer was associated with
higher serum concentrations of mono-ortho polychlorinated biphenyl (PCB) congeners 28 and
118. The odds ratio for these mono-ortho PCBs for middle and higher tertile were, respectively,
1.82 [95% confidence interval (CI), 0.90–3.70] and 2.94 (95% CI, 1.39–6.20).
α-Hexachlorocyclohexane, hexachlorobenzene, and p,p´-DDE (4,4´-dichlorodiphenyltrichloro-
ethene) showed nonsignificant increases in risk. Risk associated with mono-ortho PCBs was
slightly higher for tumors with mutations in the p53 gene but was not modiﬁed by mutations in
K-ras. Mono-ortho PCBs were further associated with transversion-type mutations in both genes.
These results generate the hypothesis that exposure to mono-ortho PCBs contributes to human
colorectal cancer development. The trend and magnitude of the association, as well as the observa-
tion of a molecular fingerprint in tumors, raise the possibility that this finding may be causal.
Key words: case–control study, colorectal cancer, K-ras mutations, organochlorines, p53 muta-
tions, PCBs. Environ Health Perspect 112:1460–1466 (2004). doi:10.1289/ehp.7143 available via
http://dx.doi.org/ [Online 15 July 2004]
Research ArticleDespite this, few studies of OC exposure
and colorectal cancer risk have been published.
Some studies in occupationally exposed
cohorts have shown mixed results (Acquavella
et al. 1996; Bertazzi et al. 1987; Brown 1987;
Cantor and Silberman 1999; Leet et al. 1996;
Wilkinson et al. 1997), whereas studies with
data on individual plasma levels are rare. One
study of colorectal cancer in children from
rural areas exposed to pesticides showed no
differences in serum OC levels compared with
controls (Caldwell et al. 1981). Higher (non-
signiﬁcant) serum concentrations of DDT and
β-HCH in cases than in controls were
reported in a small study of farmers in Egypt
(Soliman et al. 1997).
To test the hypothesis that exposure to
OCs plays an etiologic role in colorectal can-
cer, we determined serum concentrations in a
subset of samples from a hospital-based
case–control study. In addition, we investi-
gated the relationship between OC concen-
trations and mutations of the K-ras and p53
genes.
Materials and Methods
Study population. We conducted a hospital-
based case–control study to assess gene–
environment interactions in relation to colo-
rectal cancer risk. A detailed description of the
population and study methods has already
been published (Landi et al. 2003). Cases were
patients with a new diagnosis of colorectal
adenocarcinoma attending a university hospi-
tal in Barcelona, Catalonia, Spain, between
January 1996 and December 1998. Controls
were selected from admissions to the same
hospital during this period using age and sex
as frequency-matching criteria. To avoid selec-
tion bias of controls, the reason for admission
had to be a disease not previously diagnosed
for that patient. This criterion was used to
avoid inclusion of patients with chronic dis-
eases who might be repeatedly admitted to
hospital and modify their habits because of
their disease. This procedure paralleled the cri-
terion for cases, who were also newly diagnosed
incident cases. Main diagnosis groups of con-
trols were acute digestive surgery (19%), urol-
ogy (17%), gastroenterology (16%), and
orthopedic surgery (15%). The study protocol
was cleared by the ethics committee of the hos-
pital, and all individuals gave written, informed
consent to participate and for genetic analysis
of their samples to be performed.
Of 523 identified cases, there were
13 (2%) refusals and 74 (14%) exclusions,
with reasons including mental or other
impairment and death or discharge before
recruitment. We identiﬁed a total of 488 con-
trols, with 36 (7%) refusals and 22 (5%)
exclusions (reasons as described above). From
these 436 cases and 430 controls, we selected a
random sample of 140 cases and 80 controls
for OC analyses for budgetary reasons. The
sample size and imbalance in number between
cases and controls was chosen to retain statisti-
cal power for our study of K-ras and p53
mutations among cases [80% power to detect
odds ratios (ORs) of 2.25 for the exposures of
interest]. Controls for this study were selected
using strata based on age, sex, and energy
intake, the latter being used as a frequency-
matching criterion because diet is a main
source of exposure to OCs. Twelve samples
were lost or excluded because of bad quality
during laboratory analyses, and statistical tests
were conducted on 132 cases and 76 controls.
Interviews. Cases and controls were inter-
viewed by trained personnel using a structured
questionnaire. A dietary history questionnaire,
previously developed and validated in the
framework of the EPIC study [European
Prospective Investigation into Cancer and
Nutrition (EPIC) Group of Spain 1997],
focused on average food consumption 1 year
before diagnosis. Food groups based on bro-
matologic properties were calculated from
reports of items consumed. Other risk factors
measured were body mass index (BMI) at
diagnosis and 10 years before, parity in
women, and life-long history of nonsteroidal
anti-inﬂammatory drugs (NSAIDs), tobacco,
and alcohol use.
Organochlorine analysis. Selection of
OCs for analysis was based on a literature
search of commonly studied contaminants
and included representatives of industrial and
agrochemical compounds. Among the large
family of PCB congeners, those often referred
to as the ICES 7 (from International Council
for the Exploration of the Sea), were selected:
mono-ortho PCB congeners 28 and 118 and
di-ortho PCBs 52, 101, 138, 153, 180. These
PCB congeners are frequently found at high
concentrations in humans and wildlife.
Nonfasting blood samples were obtained at
diagnosis, and serum was isolated and analyzed
“blind” for OCs. We calculated lipid-corrected
concentrations of OCs by dividing serum OC
concentrations by total plasma lipid concentra-
tions estimated using the formula of Phillips
et al. (1989), and data are expressed in
nanograms of OC per gram of lipid.
OCs were analyzed by gas chromatography
after serum samples were subjected to liquid–
liquid extraction and cleanup using concen-
trated sulfuric acid and hexane (Porta et al.
1999). A mass spectrometer in negative chemi-
cal ionization mode was used to quantify α-,
β-, γ-, and δ-HCH isomers; pentachloro-
benzene (Pe-CB), HCB, PCB congeners,
p,p´-DDT, and p,p´-DDE (4,4´-dichloro-
diphenyltrichloroethene) were quantiﬁed on a
gas chromatograph with electron capture
detection. On both instruments, quantiﬁcation
was performed by external standards using
PCB-142 as an injection standard to correct
for volume. This method performed satisfacto-
rily in an international intercalibration exercise
within the Arctic Monitoring and Assessment
Programme (AMAP 2004).
Point mutations in K-ras and p53 genes,
and expression of p53 protein. Fresh tumor tis-
sue and normal mucosa samples were obtained
from surgically extracted specimens of cases.
K-ras gene mutations in codons 12 and 13
were detected and characterized by polymerase
chain reaction (PCR) followed by single-strand
conformation polymorphism (SSCP) analysis
(Tortola et al. 1999). Aspartic acid mutations
at codons 12 and 13 were conﬁrmed by means
of artiﬁcially introduced restriction fragment
length polymorphism. Similarly, p53 exons
4–9 were analyzed by PCR and SSCP followed
by direct sequencing whenever necessary.
Expression of the p53 protein was determined
by immunohistochemistry, using commercially
available antibodies (ab-6 Pantropic; Oncogene
Research Products, VWR International
GmBH, Darmstadt, Germany). We studied
microsatellite instability by analyzing five
microsatellite sequences (Gonzalez-Garcia
et al. 2000).
Statistical analysis. OC concentrations
were categorized using tertiles based on all
subjects. Some compounds were not detected
in a high proportion of individuals. For these,
the reference category consisted of values
below the detection limit (LOD). When the
proportion of individuals with detectable val-
ues was > 50%, the values were further
divided into two groups using the median
value of those with values > LOD.
Logistic regression was used to test the
association between OCs and colorectal can-
cer. When cases were subdivided into groups
according to genetic alterations, we used poly-
tomous logistic regression, comparing each
group of cases with the whole set of controls.
All analyses were adjusted for age, sex, total
energy intake, and BMI at diagnosis because
these had been used as frequency-matching
criteria or, in case of BMI, because of con-
cerns about potential confounding of OC
exposure by BMI, given that cases showing
lower BMI might have undergone lipid-
stored OC mobilization. The impact of these
adjustments on risk estimates was minimal,
however. We also excluded an association
between OCs and tumor stage that would be
indicative of bias, because more advanced
tumors are associated with greater weight loss.
Potential confounding by other variables asso-
ciated with disease (alcohol, NSAIDs, and
food groups) was explored and rejected.
These were not included in the models to
avoid losing efﬁciency in the estimates owing
to excessive stratiﬁcation.
ORs and 95% confidence intervals (CIs)
were calculated for each group compared with
the reference category. We tested for linear
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tative after assigning codes 1 to 3 to each cate-
gory deﬁned by tertiles. Interactions between
exposures and genetic alterations in tumors
were tested with logistic regression models com-
paring cases with the alteration to cases without
it. All p-values calculated were two sided.
Results
Characteristics of cases and controls are
shown in Table 1. Sex, age, and energy intake
were used as frequency-matching criteria.
BMI estimated 10 years before diagnosis was
not related to disease. In contrast, BMI at
diagnosis was inversely related to disease,
probably due to cancer-related weight loss,
although no association was found between
plasma lipids and disease, or between plasma
lipids and OC concentrations. In this popula-
tion, alcohol intake, but not smoking, was a
strong risk factor for colorectal cancer, both in
duration and in average daily consumption.
NSAIDs other than aspirin were protective
but not signiﬁcantly so.
OC levels. Lipid-corrected concentrations
of OCs are shown in Table 2. The most abun-
dant compound was p,p´-DDE, followed by
HCB and β-HCH. Summed PCB concentra-
tions were similar to those of β-HCH. The
proportions of samples with values lower than
LODs are also shown in Table 2. PCB-28
and PCB-52 were detected in only a small
proportion of cases, although the LOD was
very low. These compounds are more easily
metabolized than are other PCBs because of
the arrangement of their chlorine atoms and
their lower degree of chlorination (Borlakoglu
and Walker 1989). δ-HCH was not detected
in any individual, and although Pe-CB and
PCB-101 were detected in a few samples, their
LODs were higher than other OCs; these
three compounds were therefore excluded
from statistical analyses.
Compounds were divided into two groups
according to water solubility, and cases had
slightly higher levels than did controls of both
groups (data not shown). PCBs were grouped
according to their structure, which is related
to toxicity (ATSDR 2000; Safe 1990). Mono-
ortho PCBs 28 and 118 have a relatively
“planar” configuration compared with the
remaining, di-ortho PCBs measured here.
Exposure to mono-ortho PCBs 28 and 118 was
almost double in cases compared with controls,
whereas exposure to di-ortho PCBs was only
slightly higher for cases than for controls.
OC levels and colorectal cancer risk.
Table 3 shows median lipid-corrected concen-
trations and 5th and 95th percentiles for each
compound, separated for cases and controls.
ORs for the association of OCs with colorectal
cancer, adjusted for age, sex, BMI, and energy
Article | Howsam et al.
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Table 1. Population characteristics.
Controls Cases
No. (%) No. (%) OR (95% CI) p-Valuea
Sex
Male 43 (57) 75 (57) 1.00
Female 33 (43) 57 (43) 1.07 (0.60–1.92)
Age (years)
24–63 26 (34) 46 (35) 1.00
63–73 25 (33) 47 (36) 1.09 (0.54–2.20)
73–92 25 (33) 39 (30) 0.91 (0.45–1.83)
Energy intake (calories/day)
663–1,733 24 (32) 46 (35) 1.00
1,733–2,280 26 (34) 43 (33) 0.82 (0.39–1.73)
2,280–4,418 26 (34) 43 (33) 0.83 (0.38–1.82)
BMI
16.8–25.0 24 (32) 56 (42) 1.00 0.09
25.0–30.0 33 (43) 51 (39) 0.65 (0.34–1.25)
30.0–40.7 19 (25) 25 (19) 0.53 (0.24–1.17)
BMI 10 years before diagnosis
17.6–25.0 19 (25) 42 (32) 1.00 0.79
25.0–30.0 42 (55) 57 (43) 0.61 (0.31–1.20)
30.0–43.1 15 (20) 33 (25) 0.95 (0.41–2.18)
Plasma lipids (g/L)
2.58–4.94 26 (34) 44 (33) 1.00 0.49
4.94–5.85 21 (28) 48 (36) 1.37 (0.67–2.81)
5.85–9.55 29 (38) 40 (30) 0.79 (0.39–1.57)
Alcohol duration (years)
0 34 (45) 42 (32) 1.00 0.05
1–40 19 (25) 38 (29) 2.22 (0.93–5.30)
40–74 23 (30) 52 (39) 2.40 (1.02–5.63)
Alcohol consumption (g/day)
0 36 (47) 42 (31) 1.00 0.001
1–60 35 (46) 66 (50) 2.42 (1.13–5.17)
60–410 5 (6) 24 (18) 7.39 (2.13–25.7)
Tobacco use (menb)
Nonsmoker 9 (20) 20 (26) 1.00 0.47
Ex-smoker 23 (53) 37 (49) 0.75 (0.29–2.00)
Smoker 11 (25) 18 (24) 0.66 (0.21–2.12)
Smoking duration (years, menb)
0 9 (21) 20 (27) 1.00 0.81
1–40 20 (47) 22 (29) 0.48 (0.17–1.36)
40–79 14 (33) 33 (44) 1.05 (0.38–2.96)
Parity (women)
0–2 6 (18) 16 (28) 1.00 0.78
2–4 20 (61) 25 (44) 0.55 (0.17–1.76)
4–9 7 (21) 16 (28) 1.25 (0.31–5.11)
NSAID use
None 52 (68) 101 (76) 1.00 0.12
Aspirin 12 (15) 22 (16) 0.92 (0.42–2.04)
Other 12 (15) 9 (6) 0.43 (0.16–1.11)
aTest for linear trend adjusted for age, sex, energy intake, and BMI. bOnly 6% of women ever smoked in this population.
Table 2. Lipid-corrected serum concentrations of
OCs.
Percent of 
samples
OC Mediana (cutpoints)b LODc > LODd
p,p´-DDE 3,686 (2,574–5,565) 0.2 100
p,p´-DDT 444 (336–740) 1.5 100
HCB 1,753 (1,344–2,522) 77.9 98
α-HCH 17 (< 2.8–30) 2.8 61
β-HCH 1,057 (779–1,422) 34.4 100
γ-HCH 10 (< 1.5–46) 1.5 56
PCB-28 < 3.5 (< 3.5) 3.5 25
PCB-118 92 (< 21.0–127) 21.0 62
PCB-52 < 4.6 (< 4.6) 4.6 9
PCB-153 362 (255–487) 16.0 100
PCB-138 308 (245–404) 15.3 98
PCB-180 252 (190–333) 16.0 98
aLipid-corrected concentrations expressed as ng/g lipid.
bCutpoints were 33rd and 66th percentiles, except for com-
pounds for which the 33rd percentile was < LOD, in which
case median of measured values were used. cLipid cor-
rected (ng/g lipid) using average lipid concentration in the
population (5.44 g lipid/L serum). dProportion of samples
with values > LOD.
Table 3. Lipid-corrected serum concentrations
[median (5th–95th percentile); ng/g lipid] of OCs in
cases and controls.
OC Cases Controls
p,p´-DDE 3,936 (600–11,804) 2,977 (611–13,608)
p,p´-DDT 396 (124–2,077) 609 (137–3,848)
HCB 1,753 (487–5,777) 1,763 (720–4,848)
α-HCH 21 (< 2.8–94) 14 (< 2.8–55)
β-HCH 1,042 (315–2,971) 1,119 (345–3,654)
γ-HCH 10 (< 1.5–121) 10 (< 1.5–399)
PCB-28 < 3.5 (< 3.5–228) < 3.5 (< 3.5–43)
PCB-118 103 (< 21–319) 63 (< 21–404)
PCB-52 < 4.6 (< 4.6–49) < 4.6 (< 4.6–< 4.6)
PCB-153 381 (118–1,018) 340 (118–917)
PCB-138 327 (121–992) 301 (91–830)
PCB-180 259 (87–741) 238 (72–650)intake, are shown in Table 4. Those signifi-
cantly associated with an increased risk were
mono-ortho PCBs 28 and 118, each with indi-
vidual ORs > 2 for the more exposed category.
The OR for serum concentrations of the
mono-ortho PCB group that combines PCB-28
and PCB-118 was 1.82 (95% CI, 0.90–3.70)
in the middle tertile (LOD, 147 ng/g lipid) and
2.94 (95% CI, 1.39–6.20; p-value for trend =
0.004) for the highest tertile. Concentrations
of di-ortho PCBs were not related to disease,
nor was the classiﬁcation of OCs according to
their lipophilicity. High levels of α-HCH,
HCB, and p,p´-DDE showed a nonsigniﬁcant
increase in risk. Levels of p,p´-DDT were lower
in cases than in controls in this population.
OC levels and interaction with other vari-
ables. Dietary variables, which are both sources
of exposure and risk factors for colorectal can-
cer, were explored as potential confounders.
Speciﬁc food groups explored were vegetables,
fruit, legumes, potatoes, meat, ﬁsh, eggs, dairy
products, added fats, and pastries. Spearman’s
correlation coefficients between food groups
and serum levels of speciﬁc OCs were in general
low and nonsigniﬁcant (maximum r = 0.19).
Exceptions worth mentioning were dairy prod-
ucts, which correlated with p,p´-DDT and
PCB-101; fresh meats, which correlated with
PCB-101, PCB-153, and PCB-180; and ﬁsh,
which correlated with PCB-153 and PCB-180.
The significance of these correlations was
poor, and in addition to those correlations
mentioned, we observed several negative cor-
relations. We also used a multivariate logistic
regression model with all food groups to 
generate a “dietary propensity factor,” which
could be interpreted as a score integrating the
risk of colorectal cancer associated with diet.
Adjusting OCs for this dietary propensity fac-
tor did not modify the risk estimates, showing
again that diet was not a confounding factor.
Hence, after careful consideration, adjustment
of the analyses for food groups was found to be
unnecessary because foods were not clearly
related to serum OC levels and, more impor-
tant, did not modify the risk estimates.
An exploratory analysis of interactions
between mono-ortho PCBs and several vari-
ables was carried out. The magnitude of the
risk of colorectal cancer observed for these OCs
was not modiﬁed by sex, age, BMI, smoking,
NSAIDs use, or parity in women. Analysis of
interactions with other hormonal variables in
women could not be performed because only
six women were exposed to oral contraceptives
and only two to postmenopausal hormone
replacement treatments. Because alcohol was
an important risk factor in this study and alco-
hol intake produces metabolic induction simi-
lar to that produced by some OCs (Mochizuki
and Yoshida 1989), interactions between OCs
and alcohol were explored in detail, but none
was signiﬁcant.
OC levels and mutations at the K-ras and
p53 genes. K-ras was mutated in 50 (38%)
cases. Most frequent mutations were GAT
(n = 16) and GTT (n = 15) in codon 12. In
6 cases, codon 13 was mutated to GAC.
Other, less frequent mutations in codon 12
were TGT (n = 5), AGT (n = 4), GCT (n = 3),
and CGT (n = 1). Twenty-six mutations were
transitions (G:C → A:T), and 24 were trans-
versions (G:C → T:A).
Tumor suppressor gene p53 was mutated
in 59 (60%) of the tumors analyzed (data not
available for 34 cases). Twenty-four mutations
were located in hotspots: codon 175 (n = 4),
codon 245 (n = 3), codon 248 (n = 3), codon
273 (n = 6), and codon 282 (n = 8). Four
cases harbored mutations at codon 158, the
remaining being detected at 24 different
codons with frequencies ≤ 2. Forty mutations
were transitions, and 15 were transversions; in
the remaining four cases, deletions were
detected. The most frequent base changes
were C→T and G→A, each in 17 cases,
mainly at hotspot sites. G→T changes were
observed in eight cases and distributed with
a nonclustered profile. The immunohisto-
chemical analyses showed that 76% of the
cases overexpressed the p53 protein.
Table 5 shows the analysis of selected OCs
where the cases have been stratiﬁed by muta-
tions in K-ras and p53. This analysis is based
on polytomous logistic regression, and each
group of cases is compared with controls in a
uniﬁed model. Exposure to mono-ortho PCBs
28 and 118 increased risk in similar magni-
tude for both mutated and wild-type K-ras.
PCB-118, but not PCB-28, showed higher
risk for p53-mutated tumors, although the
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Table 4. Risk of colorectal cancer associated with organochlorine body burden.
Controls Cases
No. (%) No. (%) OR (95% CI) p-Valuea
p,p´-DDE
Low 31 (41) 38 (29) 1.00 0.19
Medium 21 (28) 49 (37) 2.17 (1.03–4.54)
High 24 (32) 45 (34) 1.60 (0.79–3.25)
p,p´-DDT
Low 25 (33) 44 (33) 1.00 0.12
Medium 18 (24) 52 (39) 1.58 (0.74–3.36)
High 33 (43) 36 (27) 0.56 (0.27–1.17)
HCB
Low 29 (38) 40 (30) 1.00 0.23
Medium 22 (29) 47 (36) 1.72 (0.83–3.54)
High 25 (33) 45 (34) 1.60 (0.62–4.15)
α-HCH
Low 33 (43) 48 (36) 1.00 0.081
Medium 27 (36) 37 (28) 0.99 (0.49–1.98)
High 16 (21) 47 (36) 2.02 (0.95–4.29)
β-HCH
Low 26 (34) 44 (33) 1.00 0.81
Medium 23 (30) 45 (34) 1.14 (0.55–2.36)
High 27 (36) 43 (33) 0.88 (0.39–2.02)
γ-HCH
< LOD 30 (39) 61 (46) 1.00 0.28
Medium 22 (29) 36 (27) 0.79 (0.38–1.61)
High 24 (32) 35 (27) 0.69 (0.34–1.38)
PCB-28
< LOD 65 (86) 91 (69) 1.00 0.006
> LOD 11 (14) 41 (31) 2.75 (1.29–5.83)
PCB-118
< LOD 36 (47) 43 (33) 1.00 0.045
Medium 20 (26) 39 (30) 1.63 (0.80–3.31)
High 20 (26) 50 (38) 2.02 (1.00–4.08)
PCB-52
< LOD 69 (91) 120 (91) 1.00 0.77
> LOD 7 (9) 12 (9) 1.16 (0.42–3.19)
PCB-153
Low 30 (39) 39 (30) 1.00 0.57
Medium 22 (29) 48 (36) 1.50 (0.74–3.07)
High 24 (32) 45 (34) 1.22 (0.59–2.52)
PCB-138
Low 26 (34) 43 (33) 1.00 0.79
Medium 26 (34) 44 (33) 0.85 (0.41–1.75)
High 24 (32) 45 (34) 0.90 (0.43–1.90)
PCB-180
Low 29 (38) 41 (31) 1.00 0.63
Medium 24 (32) 44 (33) 1.20 (0.59–2.42)
High 23 (30) 47 (36) 1.19 (0.57–2.49)
ap-Value for trend adjusted for age, sex, energy intake, and BMI.interaction was not signiﬁcant. This stratiﬁca-
tion of cases by genetic alterations also showed
some signiﬁcant interactions with other OCs.
High levels of p,p´-DDE were associated with
increased risk of cancer with wild-type K-ras.
Also, p,p´-DDE and α-HCH had signiﬁcant
effects on p53-mutated tumors. A similar pat-
tern was evident when tumors were stratiﬁed
according to p53 overexpression: p,p´-DDE
and PCB-118 increased the risk only for
tumors overexpressing p53 protein. Tumors
with microsatellite instability were rare (n = 11,
8%), and these patients had similar OC levels
to other cases.
Overall, 81% of the tumors harbored
K-ras and/or p53 gene mutations, and a com-
bined analysis was performed. Exposure to
high levels of the mono-ortho PCB-118 was
associated with more mutations (OR = 2.89;
95% CI, 0.66–12.7), with transversions three
times more likely than transitions (Table 6).
Other OCs analyzed in this way were not
related to the type of mutation.
Discussion
OCs have previously been associated with
increased risk of colorectal cancers in studies of
occupationally exposed individuals (Acquavella
et al. 1996; Soliman et al. 1997; Wilkinson
et al. 1997). Other studies have failed to show
this association (Hardell 1981; Hoar et al.
1985; Settimi et al. 2001) or even have shown
inverse associations with colon cancer (Cantor
and Silberman 1999; Wang et al. 2002). These
mixed results are not surprising because most
occupational studies lack individual exposure
indicators and are prone to confounding. To
overcome these limitations, we studied a popu-
lation not occupationally exposed using serum
OC levels as exposure markers. We found an
elevated risk of colorectal cancer associated
with high levels of mono-ortho PCBs 28 and
118. Other abundant OCs such as p,p´-DDE
and α-HCH also showed an increased risk of
relevant magnitude; although the associations
for these OCs were not significant for the
entire population of cases, they were signiﬁcant
for the subset of tumors harboring mutations
of the p53 gene.
We have taken serum concentrations of
OCs as indicative of the body burden. Serum
concentrations are strongly correlated with
those in adipose tissue and feces and reﬂect the
historical legacy of uptake and depuration, and
as such, they may be taken as markers for long-
term, low-level exposure (Alcock et al. 2000;
Juan et al. 2002; Moser and McLachlan 2001).
Many studies that also used plasma OC con-
centrations as exposure markers have reported
mixed results for breast cancer (Calle et al.
2002) and non-Hodgkin lymphoma (Cantor
et al. 2003; De Roos et al. 2003; Rothman
et al. 1997) but increased risk of pancreatic
cancer (Hoppin et al. 2000; Porta et al. 1999;
Slebos et al. 2000). Altogether, these results
suggest that a role for OCs in the etiology of
several tumors is likely. Nevertheless, the
mechanisms underlying carcinogenicity will
differ among both OCs and target organs
because chemical properties and toxicity
mechanisms of these compounds are diverse.
In addition, target organs differing in lipid
content might determine distinct degree of
local exposure.
In our population, high body burdens of
mono-ortho PCBs 28 and 118 were associated
with an elevated risk of colorectal cancer.
These OCs are among the most toxic of the
PCBs, together with non-ortho PCBs. The
relatively ﬂat (or “planar”) orientation of their
biphenyl rings allows them to bind to the aryl
hydrocarbon (Ah) receptor in a similar way to
polychlorinated dibenzodioxins and dibenzo-
furans and may be responsible for our ﬁnding
(Safe 1990). This binding induces phase I and
phase II metabolic enzymes; mono-ortho PCBs
may therefore induce CYP1A and CYP2B
enzymes that, in the absence of substrate, can
produce reactive oxygen species. Although
PCB-118 has a toxic equivalency factor (TEF)
of 0.0001, based on its toxicity relative to
2,3,7,8-tetrachlorinated dibenzo-p-dioxin (Van
den Berg et al. 1998), PCB-28 has not been
assigned a TEF under this scheme and may
not, therefore, bind strongly to the Ah receptor
and/or significantly induce CYP enzymes.
Nevertheless, higher serum levels of PCB-28
were associated with increased risk of colon
cancer in this study. Some studies on breast
cancer have also reported increased risk being
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Table 5. Colorectal cancer risk for selected organochlorines in relation to K-ras and p53 mutations.
Wild-type Mutated
No. (%) OR (95% CI) No. (%) OR (95% CI) p-Valuea
K-ras
p,p´-DDE
Low 16 (20) 1.00 22 (44) 1.00 0.012
Medium 34 (41) 3.51 (1.49–8.24) 15 (30) 1.07 (0.42–2.72)
High 32 (39) 2.78 (1.21–6.35) 13 (26) 0.72 (0.29–1.81)
α-HCH
Low 28 (34) 1.00 20 (40) 1.00 0.55
Medium 27 (33) 1.22 (0.57–2.61) 10 (20) 0.64 (0.25–1.66)
High 27 (33) 2.16 (0.94–4.97) 20 (40) 1.75 (0.70–4.37)
PCB-28
< LOD 56 (68) 1.00 35 (70) 1.00 0.88
> LOD 26 (32) 2.78 (1.24–6.25) 15 (30) 2.83 (1.13–7.06)
PCB-118
< LOD 26 (32) 1.00 17 (34) 1.00 0.42
Medium 25 (30) 1.78 (0.81–3.90) 14 (28) 1.35 (0.53–3.43)
High 31 (38) 2.27 (1.04–4.96) 19 (38) 1.64 (0.67–4.01)
p53
p,p´-DDE
Low 12 (31) 1.00 11 (19) 1.00 0.047
Medium 16 (41) 2.24 (0.81–6.16) 20 (34) 2.94 (1.11–7.76)
High 11 (28) 1.09 (0.39–3.05) 28 (47) 3.44 (1.39–8.47)
α-HCH
Low 18 (46) 1.00 16 (27) 1.00 0.045
Medium 10 (26) 0.76 (0.29–2.01) 17 (29) 1.39 (0.58–3.35)
High 11 (28) 1.22 (0.44–3.34) 26 (44) 3.44 (1.40–8.45)
PCB-28
< LOD 29 (74) 1.00 44 (75) 1.00 0.98
> LOD 10 (26) 2.16 (0.79–5.91) 15 (25) 2.06 (0.85–5.01)
PCB-118
< LOD 14 (36) 1.00 18 (31) 1.00 0.19
Medium 13 (33) 1.72 (0.65–4.53) 13 (22) 1.31 (0.53–3.26)
High 12 (31) 1.40 (0.52–3.75) 28 (47) 2.79 (1.22–6.37)
ap-Value for interaction between OC and the genetic alteration adjusted for age, sex, energy intake, and BMI; tests for dif-
ferences in the OR between wild-type and mutated cases.
Table 6. Colorectal cancer risk for PCB-118 in relation to K-ras and p53 mutation type.
Transitionsa Transversionsa
No. (%) OR (95% CI) No. (%) OR (95% CI) p-Valueb
PCB-118
< LOD 20 (37) 1.00 6 (18) 1.00 0.071
Medium 17 (32) 1.09 (0.28–4.28) 12 (35) 3.29 (0.66–16.4)
High 17 (32) 1.93 (0.41–9.09) 16 (47) 6.52 (1.16–36.6)
Trend test p-valuec 0.42 0.038
aMutations in K-ras and p53 classified as transitions (G:C→A:T) or transversions (G:C→T:A). bp-Value for interaction
between PCB-118 and the mutation type; tests for differences in the OR between transitions and transversions. cTrend
test p-value for the speciﬁc mutation type adjusted for age, sex, energy intake, and BMI.limited to mono-ortho PCBs (Aronson et al.
2000; Demers et al. 2002; Lucena et al. 2001).
PCBs themselves are hydroxylated by
cytochrome P450 enzymes, and their metabo-
lites have been shown to induce DNA
adducts in vitro (McLean et al. 1996). We
have not observed a clear differential risk for
PCB-28 or PCB-118 in relation to K ras or
p53 mutations. However, when mutations in
both genes were classified according to their
molecular nature, an association between
transversions (less likely to occur sponta-
neously) and exposure to mono-ortho PCBs
was observed. This could be interpreted as
indirect evidence for a molecular fingerprint
associated with exposure to these pollutants.
The role of other OCs in colorectal cancer
risk may be more complex. Compounds such
as p,p´-DDE and α-HCH that had an overall
moderate association with colorectal cancer
showed a signiﬁcant increase in risk for tumors
with mutation of the p53 gene. A similar result
was reported in a Danish study, where higher
risk of breast cancer with mutated p53 was
observed among women exposed to high levels
of dieldrin and PCBs (Hoyer et al. 2002). In
our population, p,p´-DDE also increased risk
for tumors with wild-type K-ras but not when
this oncogene was mutated. Previous studies in
pancreatic cancer have provided mixed results
regarding OC exposure and K-ras mutation
status associated with DDE levels (Porta et al.
1999; Slebos et al. 2000).
Several factors suggest that these ﬁndings
may be causal: the strength and trend of the
associations observed; the restriction of the
ﬁndings to mono-ortho PCBs that have a rela-
tively planar, dioxin-like structure; the exis-
tence of similar ﬁndings in tumors from other
organs; the plausibility of carcinogenic mecha-
nisms; and the association with speciﬁc muta-
tion types. We are aware, however, that this
study also has several limitations. Owing to the
limitations of our analytical method, we did
not study non-ortho PCBs that have a greater
affinity for the Ah receptor than do mono-
ortho PCBs as a result of their “coplanar” mole-
cular structure, which may have strengthened
our hypothesis. The retrospective assessment of
exposure in the case–control design is not
ideal, and the use of hospital controls may
introduce information and selection bias. We
minimized these biases by careful design, the
use of validated questionnaires administered by
trained interviewers, and robust analytical
methods. However, potential sources of non-
differential bias would tend to decrease the
magnitude of any positive relationship; in par-
ticular, if OC exposure increased the risk of
hospital admission, this would bias the associa-
tions toward the null hypothesis. Furthermore,
potential confounding factors were explored in
detail and rejected. Special effort was devoted
to explore whether the weight loss observed
among cases could explain the results, because
OCs accumulate in lipids, and changes in
BMI due to metabolism of adipose tissue in
cancer patients could result in higher serum
levels of OCs. However, three observations
combine to negate this possibility: a) adjusting
for BMI had only a minor effect on risk
estimates; b) although more advanced cases
exhibited severe weight loss, there was no asso-
ciation between OC levels and tumor stage;
and c) if lipid mobilization was the reason for
observing higher OC levels among cases, this
would be true for all OCs but especially the
more lipophilic compounds, whereas we
observed increased risk only for selected OCs,
and these were less lipophilic than p,p´-DDT
and PCB-138, PCB-153, and PCB-180, for
which no increased risk was observed.
Nevertheless, we cannot exclude chance as an
explanation of some of the results because this
study was conceived as exploratory or hypoth-
esis generating and we performed many statis-
tical comparisons.
In conclusion, these results suggest that
exposure to mono-ortho PCBs is associated
with an increased risk of colorectal cancer.
The trend and magnitude of the association
and the specific toxic action of these PCBs,
linked with transversion-type mutations, sug-
gest that this finding may be causal. This
hypothesis merits conﬁrmation in other stud-
ies that would benefit from including other
mono-ortho PCBs, as well as non-ortho PCBs
and perhaps dioxins/furans.
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